Additional intranasal oxytocin to escitalopram improves depressive symptoms in resistant depression: An open trial

European Psychiatry

Volumn 30, Issue 1, 2015, Pages 65-68

  Scantamburlo, G ^a   Hansenne, M ^a   Geenen, V ^a   Legros, J J ^a   Ansseau, M ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Anxiety; Intranasal oxytocin; Major depression

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ESCITALOPRAM; OXYTOCIN; CITALOPRAM;

ADULT; ANTIDEPRESSANT ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; FEMALE; HAMILTON DEPRESSION RATING SCALE; HUMAN; MALE; OPEN STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE ENJOYMENT AND SATISFACTION QUESTIONNAIRE; QUESTIONNAIRE; STATE TRAIT ANXIETY INVENTORY; TRANQUILIZING ACTIVITY; TREATMENT RESISTANT DEPRESSION; CLINICAL TRIAL; DEPRESSION; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; TREATMENT OUTCOME;

ADMINISTRATION, INTRANASAL; ADULT; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; DEPRESSION; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; OXYTOCIN; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME;

EID: 84920983063     PISSN: 09249338     EISSN: 17783585     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2014.08.007     Document Type: Article

References (28)

1. Cardoso C., Ellenbogen M., Linnen A. Acute intranasal oxytocin improves positive self-perceptions of personality. Psychopharmacology 2012, 220:741-749.
2. Domes G., Lischke A., Berger C., Grossmann A., Hauenstein K., Heinrichs M., et al. Effects of intranasal oxytocin on emotional face processing in women. Psychoneuroendocrinology 2010, 35:83-93.
3. Ellenbogen M.A., Linnen A.M., Cardoso C., Joober R. Intranasal oxytocin impedes the ability to ignore task-irrelevant facial expressions of sadness in students with depressive symptoms. Psychoneuroendocrinology 2013, 38:387-398.
4. Endicott J., Nee J., Harrison W., Blumenthal R. Quality of life enjoyment and satisfaction questionnaire: a new measure. Psychopharmacol Bull 1993, 29:321-326.
5. Emiliano A., Cruz T., Pannoni V., et al. The interface of oxytocin-labeled cells and serotonin. Neuropsychopharmacology 2006, 11:1-12.
6. Forkmann T., Scherer A., Boecker M., et al. The clinical global Impression scale and the influence of patient or staff perspective on outcome. BMC Psychiatry 2011, 11(1):83.
7. Furman D.J., Chen M.C., Gotlib I.H. Variant in oxytocin receptor gene is associated with amygdala volume. Psychoneuroendocrinology 2011, 36:891-897.
8. Heinrichs M., Baumgartner T., Kirschbaum C., Ehlert U. Social support and oxytocin interact to suppress cortisol and subjective responses to psychosocial stress. Biol Psychiatry 2003, 54:1389-1398.
9. Keating C., Dawood T., Barton D., Lambert G., Tilbrook A. Effects of selective serotonin reuptake inhibitor treatment on plasma oxytocin and cortisol in major depressive disorder. BMC Psychiatry 2013, 29(13):124.
10. Lischke A., Gamer M., Berger C., Grossmann A., Hauenstein K., Heinrichs M., et al. Oxytocin increases amygdala reactivity to threatening scenes in females. Psychoneuroendocrinology 2012, 37:1431-1438.
11. Macdonald K., Feifel D. Helping oxytocin deliver: considerations in the development of oxytocin-based therapeutics for brain disorders. Front Neurosci 2013, 7:1-21.
12. Mah B.L., Van Ijzendoorn M.H., Smith R., Bakermans-Kranenburg M.J. Oxytocin in postnatally depressed mothers: its influence on mood and expressed emotion. Prog in Neuropsychopharmacol Biol Psychiatr 2013, 40:267-272.
13. Matsuki M., Matsushita H., Tomizawa K., Matsui H. Oxytocin: a therapeutic target for mental disorder. J Physiol Sci 2012, 62:441-444.
14. Mendlewicz J., Crisafulli C., Calati R., Kocabas N.A., Massat I., Linotte S., et al. Influence of COX-2 and OXTR polymorphisms on treatment outcome in treatment resistant depression. Neurosci Lett 2012, 10(516):85-88.
15. Meyer-Lindenberg A., Domes G., Kirsch P., Heinrichs M. Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine. Nat Rev Neurosci 2011, 19(12):524-538.
16. Miller G. The promise and perils of oxytocin. Science 2013, 339:267-269.
17. Legros J.J. Inhibitory effect of oxytocin on corticotrope function in humans: are vasopressin and oxytocin ying-yang neurohormones?. Psychoneuroendocrinology 2011, 26:649-655.
18. Okimoto N., Bosch O.J., Slattery D.A., Pflaum K., Matsushita H., Wei F.Y., et al. RGS2 mediates the anxiolytic effect of oxytocin. Brain Res 2012, 9(1453):26-33.
19. Ozsoy S., Esel E., Kula M. Serum oxytocin levels in patients with depression and the effects of gender and antidepressant treatment. Psychiatry Res 2009, 30(169):249-252.
20. Parker K.J., Kenna H.A., Zeitzer J.M., Keller J., Blasey C.M., Amico J.A., et al. Preliminary evidence that plasma oxytocin levels are elevated in major depression. Psychiatry Res 2010, 178:359-362.
21. Pincus D., Kose S., Arana A., Johnson K., Morgan P., Borckardt J., et al. Inverse effects of oxytocin on attributing mental activity to others in depressed and healthy subjects: a double-blind placebo controlled fMRI study. Front Psychiatr 2010, 1.
22. Scantamburlo G., Hansenne M., Fuchs S., Pitchot W., Maréchal P., Pequeux C., et al. Plasma oxytocin levels and anxiety in patients with major depression. Psychoneuroendocrinology 2007, 32:407-410.
23. Scantamburlo G., Ansseau M., Geenen V., Legros J.J. Intranasal oxytocin as an adjunct to escitalopram in major depression. J Neuropsychiatry Clin Neurosci 2011, 23:2.
24. Spielberger C.D., Gorsuch R.L., Lushene R., Vagg P.R., Jacobs G.A. Manual for the state-trait anxiety inventory. Consulting psychologists' press 1983, Palo Alto, CA.
25. Turan T., Uysal C., Asdemir A., Kilic E. May oxytocin be a trait marker for bipolar disorder?. Psychoneuroendocrinology 2013, 38:2890-2896.
26. Uvnäs-Moberg K. Antistress pattern induced by oxytocin. News Physiol Sci 1998, 13:22-25.
27. van Ijzendoorn M., Bhandari R., van der Veen R., Grewen K., Bakermans-Kranenburg M.J. Elevated salivary levels of oxytocin persist more than seven hours after intranasal administration. Front Neurosci 2012, 6:174.
28. Zink C., Meyer-Lindenberg A. Human neuroimaging of ocytocin and vasopressin in social cognition. Horm Behav 2012, 61:400-409.